

Manulife Global Fund
Société d'investissement à capital variable
Registered office: 31, Z.A. Bourmicht, L-8070 Bertrange
Grand Duchy of Luxembourg

This document is important and requires your immediate attention. If in doubt, you should seek independent professional advice.

**Notice to Shareholders
("Notice")**

3 October 2018

Dear Shareholder

We are writing to inform you of certain changes to Manulife Global Fund (the "**Company**"). Words and phrases used in this Notice shall, unless otherwise provided, have the same meanings as are ascribed to them in the prospectus of the Company (the "**Prospectus**").

Wind-up of Cyprus Subsidiary

As currently disclosed in the Prospectus, the Emerging Eastern Europe Fund and the Russia Equity Fund (the "**Sub-Funds**") may invest in the Russian market, either directly or indirectly, through a wholly-owned subsidiary of the Company incorporated in Cyprus, namely GFM Holdings (Cyprus) Limited (the "**Cyprus Subsidiary**") in order to benefit from the existing double taxation treaty between Cyprus and Russia. Having taken into consideration recent changes to the interpretation of such treaty arrangements by the relevant taxation authorities and therefore the resulting tax treatment and position of the Cyprus Subsidiary thereunder, together with the ongoing annual administrative costs related to the operation of the Cyprus Subsidiary, the board of directors of the Company has determined that the continued use of the Cyprus Subsidiary for investments is no longer beneficial to the Sub-Funds and accordingly it is in the best interest of the Company and the Sub-Funds to terminate the operations of and liquidate the Cyprus Subsidiary.

As a preliminary step, the Sub-Funds will cease further investments via the Cyprus Subsidiary and any new investments will instead be made by the Sub-Funds directly. Concurrently, arrangements will be made to transfer each of the existing investments held by the Cyprus Subsidiary to the relevant Sub-Fund, with all resulting proceeds received from the Sub-Funds being applied either towards the outstanding balance of the existing loan facility granted to the Cyprus Subsidiary by the Company (as described in paragraph 5 of Appendix II of the Prospectus), or otherwise distributed as dividends to the Company. Once such transfers are completed, the Company will commence the termination and liquidation process for the Cyprus Subsidiary, which is currently expected to be completed in Q2 2019.

All costs and expenses in connection with the above will be borne by the General Adviser and Distributor of the Company. Please note that, except as otherwise described above, the above changes (i) will have no effect on the investment objective, strategy and risk profiles of the Sub-Funds, (ii) will not result in any change in the operations and/or manner in which the Company and the Sub-Funds are being managed, (iii) will not lead to an increase in the fees to be borne by any of the Sub-Funds or their investors, and (iv) will not materially prejudice any of the rights or interests of the existing investors of the Sub-Funds.

For the avoidance of doubt, the above does not constitute any tax advice and should not be treated by Shareholders as such. You should therefore seek independent professional advice on any applicable tax implications in the country of your respective citizenship, domicile or residence.

General

For Hong Kong Shareholders Only: The Prospectus, the Hong Kong Covering Document and the Product Key Facts Statements of the relevant Sub-Funds are available from the office of the Hong Kong Representative and are also available at www.manulifefunds.com.hk¹.

¹ This website has not been reviewed by the SFC.

Shareholders requiring further information about any of the matters set out in this Notice may contact the Administrator of the Company, Citibank Europe plc, Luxembourg Branch, at telephone number (352) 45 14 14 258 or fax number (352) 45 14 14 332 or the Hong Kong Distributor, Manulife Asset Management (Hong Kong) Limited, at telephone number (852) 2108 1110 or fax number (852) 2810 9510 at any time during normal business hours.

To the best of the knowledge and belief of the Directors (who have taken all reasonable care to ensure that such is the case), the information contained in this Notice is in accordance with the facts and does not omit anything likely to affect the import of such information as at the date of this Notice. The Directors accept responsibility for the accuracy of the contents of this Notice accordingly.

For and on behalf of the Board